Wells Fargo & Company MN Has $11.44 Million Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Wells Fargo & Company MN cut its stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 11.7% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 863,678 shares of the company’s stock after selling 114,324 shares during the period. Wells Fargo & Company MN’s holdings in Takeda Pharmaceutical were worth $11,435,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Versant Capital Management Inc purchased a new position in shares of Takeda Pharmaceutical during the 4th quarter valued at $26,000. Wilmington Savings Fund Society FSB purchased a new position in Takeda Pharmaceutical in the third quarter valued at about $40,000. BNP Paribas Financial Markets grew its stake in Takeda Pharmaceutical by 416.0% in the third quarter. BNP Paribas Financial Markets now owns 3,220 shares of the company’s stock valued at $46,000 after purchasing an additional 2,596 shares in the last quarter. Farther Finance Advisors LLC increased its position in Takeda Pharmaceutical by 123.6% in the 4th quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company’s stock worth $47,000 after purchasing an additional 1,976 shares during the last quarter. Finally, Crowley Wealth Management Inc. purchased a new stake in shares of Takeda Pharmaceutical during the 4th quarter worth about $52,000. Institutional investors and hedge funds own 9.17% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley raised Takeda Pharmaceutical from an “equal weight” rating to an “overweight” rating in a research note on Wednesday, April 2nd.

Takeda Pharmaceutical Stock Performance

Shares of TAK opened at $14.55 on Wednesday. The firm has a market cap of $46.28 billion, a price-to-earnings ratio of 36.36, a price-to-earnings-growth ratio of 0.24 and a beta of 0.39. The company’s fifty day moving average is $14.50 and its 200-day moving average is $13.90. The company has a quick ratio of 0.72, a current ratio of 1.31 and a debt-to-equity ratio of 0.63. Takeda Pharmaceutical Company Limited has a 12 month low of $12.58 and a 12 month high of $15.37.

Takeda Pharmaceutical (NYSE:TAK) last posted its earnings results on Thursday, January 30th. The company reported $0.42 EPS for the quarter, topping the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. Equities analysts expect that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current fiscal year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.